The Aroon Indicator for NRXP entered a downward trend on February 21, 2025. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 296 similar instances where the Aroon Indicator formed such a pattern. In of the 296 cases the stock moved lower. This puts the odds of a downward move at .
The 10-day RSI Indicator for NRXP moved out of overbought territory on January 15, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on February 11, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on NRXP as a result. In of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for NRXP turned negative on January 22, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .
NRXP moved below its 50-day moving average on February 19, 2025 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NRXP declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 50-day moving average for NRXP moved above the 200-day moving average on January 31, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where NRXP advanced for three days, in of 202 cases, the price rose further within the following month. The odds of a continued upward trend are .
NRXP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NRXP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (12.481). P/E Ratio (0.358) is within average values for comparable stocks, (84.446). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.603). NRXP has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (0.000) is also within normal values, averaging (251.221).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NRXP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
is a blank check company, which engages in a stock exchange, asset acquisition, stock purchase, and reorganization
Industry Biotechnology
A.I.dvisor indicates that over the last year, NRXP has been closely correlated with RNAC. These tickers have moved in lockstep 86% of the time. This A.I.-generated data suggests there is a high statistical probability that if NRXP jumps, then RNAC could also see price increases.
Ticker / NAME | Correlation To NRXP | 1D Price Change % | ||
---|---|---|---|---|
NRXP | 100% | -6.94% | ||
RNAC - NRXP | 86% Closely correlated | -1.89% | ||
NCNA - NRXP | 85% Closely correlated | +2.83% | ||
SNPX - NRXP | 84% Closely correlated | +1.06% | ||
AGEN - NRXP | 83% Closely correlated | -3.77% | ||
ALLR - NRXP | 81% Closely correlated | +1.44% | ||
More |